Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer.
immune checkpoint inhibitors
metabolomics
non-small cell lung cancer
nuclear magnetic resonance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Nov 2020
30 Nov 2020
Historique:
received:
02
11
2020
revised:
25
11
2020
accepted:
27
11
2020
entrez:
3
12
2020
pubmed:
4
12
2020
medline:
4
12
2020
Statut:
epublish
Résumé
In the treatment of advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitors have shown remarkable results. However, not all patients with NSCLC respond to this drug treatment or receive durable benefits. Thus, patient stratification and selection, as well as the identification of predictive biomarkers, represent pivotal aspects to address. In this framework, metabolomics can be used to support the discrimination between responders and non-responders. Here, metabolomics was used to analyze the sera samples from 50 patients with NSCL treated with immune checkpoint inhibitors. All the samples were collected before the beginning of the treatment and were analyzed by NMR spectroscopy and multivariate statistical analyses. Significantly, we show that the metabolomic fingerprint of serum acts as a predictive "collective" biomarker to immune checkpoint inhibitors response, being able to predict individual therapy outcome with > 80% accuracy. Metabolomics represents a potential strategy for the real-time selection and monitoring of patients treated with immunotherapy. The prospective identification of responders and non-responders could improve NSCLC treatment and patient stratification, thus avoiding ineffective therapeutic strategies.
Identifiants
pubmed: 33265926
pii: cancers12123574
doi: 10.3390/cancers12123574
pmc: PMC7760033
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Sci Rep. 2019 Mar 11;9(1):4128
pubmed: 30858406
Genome Med. 2020 Mar 30;12(1):33
pubmed: 32228719
JCI Insight. 2020 Jan 30;5(2):
pubmed: 31855576
Cancer Res. 2012 Jan 1;72(1):356-64
pubmed: 22080567
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Mol Oncol. 2017 May;11(5):517-533
pubmed: 28258651
Ann Transl Med. 2018 Nov;6(Suppl 1):S27
pubmed: 30613602
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Biotechnol. 2019 Sep 25;52:25-34
pubmed: 31022482
Clin Cancer Res. 2009 Jan 15;15(2):431-40
pubmed: 19147747
Nat Rev Drug Discov. 2016 Jul;15(7):473-84
pubmed: 26965202
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Matern Fetal Neonatal Med. 2014 Apr;27(6):537-42
pubmed: 23844701
Metabolomics. 2015;11(6):1769-1778
pubmed: 26491424
Semin Oncol. 2017 Apr;44(2):132-135
pubmed: 28923211
Oncologist. 2008;13 Suppl 2:19-21
pubmed: 18434634
Cell Commun Signal. 2019 Aug 28;17(1):108
pubmed: 31455353
Clin Cancer Res. 2017 Mar 15;23(6):1422-1431
pubmed: 28082280
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nature. 2008 Oct 23;455(7216):1054-6
pubmed: 18948945
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Int Immunopharmacol. 2018 May;58:125-135
pubmed: 29579717
Ann Oncol. 2019 Oct 1;30(10):1660-1666
pubmed: 31529107
Lancet Respir Med. 2018 Oct;6(10):771-781
pubmed: 30100403
J Biomol NMR. 2011 Apr;49(3-4):231-43
pubmed: 21380509
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Prog Nucl Magn Reson Spectrosc. 2017 Nov;102-103:1-14
pubmed: 29157489
Nat Commun. 2019 Sep 25;10(1):4346
pubmed: 31554815
Angew Chem Int Ed Engl. 2019 Jan 21;58(4):968-994
pubmed: 29999221
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
J Proteome Res. 2020 Feb 7;19(2):949-961
pubmed: 31899863
Semin Oncol. 2014 Feb;41(1):126-32
pubmed: 24565586
Sci Rep. 2020 Jun 26;10(1):10491
pubmed: 32591596
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
J Transl Med. 2020 Feb 3;18(1):49
pubmed: 32014010
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
J Proteome Res. 2015 Jul 2;14(7):2951-62
pubmed: 26055080
Nutrients. 2019 Dec 27;12(1):
pubmed: 31892215
Elife. 2020 May 05;9:
pubmed: 32367803
Mol Syst Biol. 2011 Aug 30;7:525
pubmed: 21878913